Mortality Impact of Antiplatelets on Hospitalized Patients With CAP
NEW ORLEANS, LA—Thirty-day community-acquired pneumonia (CAP) mortality risk was reduced by 45% among hospitalized patients who were taking antiplatelet drugs prior to hospitalization, according to research presented at IDWeek 2016.
"Our data suggest that modifying excessive inflammatory and coagulatory responses may be an important intervention to improve outcomes in hopspitalized patients with CAP," said Paula Peyrani, MD, of the University of Louisville, in Louisville, KY.
The analysis failed to identify significant differences in length of hospital stay or time to clinical stability, she noted.
In CAP, poor clinical outcomes may be due to the excessive inflammatory and/or coagulatory state. Dr. Peyrani and her colleagues hypothesized that patients who are prescribed antiplatelets may therefore have a decreased risk of mortality once hospitalized for CAP.
They conducted a secondary analysis of patients enrolled in the the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study to evaluate the hypothesized association between antiplatelet agents and CAP mortality risk. Their analyses included 3,337 patients hospitalized with the diagnosis of CAP between 2009 and 2015, of whom 639 were receiving antiplatelet medication (such as aspirin, ticlopidine, dipyridamole, clopidogrel, tirofiban, eptifibatide, or abciximab); 2,698 patients were not.
The adjusted multivariate risk ratio for 30-day mortality for patients on antiplatelet medication was 0.55 (P<0.001) vs. patients who were not on these drugs. (The unadjusted univariate P value was 0.051.)
"Our preliminary data can be used to design a prospective randomized study evaluating current standard of care versus current standard of care plus the addition of antiplatelet medication in hospitalized patients with CAP," Dr. Peyrani concluded.